SCHEMBL4002380

SCHEMBL4002380

O=C(O)N1CCC(c2ccccc2)CC1CO

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 3/20 0.46
AKR1C3 P42330 1/20 0.45
AKR1C1 Q04828 1/20 0.45
ALDH1A1 P00352 3/20 0.43
SIGMAR1 Q99720 1/20 0.43
POLB P06746 1/20 0.43
GAA P10253 2/20 0.42
LMNA P02545 1/20 0.42
KMT2A Q03164 1/20 0.42
RIPK1 Q13546 2/20 0.40
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
DRD2 P14416 1/20 0.40
UTS2R Q9UKP6 1/20 0.40
HSD11B1 P28845 1/20 0.40
BACE1 P56817 1/20 0.40
MCHR1 Q99705 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25362718 0.86 AKR1C3 (0.41) SLC18A3AKR1C3AKR1C1ALDH1A1SIGMAR1
SCHEMBL5576810 0.86 AKR1C3 (0.41) SLC18A3AKR1C3AKR1C1ALDH1A1SIGMAR1
SCHEMBL25362834 0.86 AKR1C3 (0.41) SLC18A3AKR1C3AKR1C1ALDH1A1SIGMAR1
SCHEMBL28001883 0.82 DRD2 (0.50) DRD2
SCHEMBL1659079 0.79 MEN1 (0.54) ALDH1A1KMT2ADRD2MAPT
SCHEMBL28171451 0.78 AKR1C3 (0.47) SLC18A3AKR1C3AKR1C1ALDH1A1SIGMAR1
SCHEMBL29136131 0.75 RIPK1 (0.49) SLC18A3AKR1C3AKR1C1ALDH1A1SIGMAR1
SCHEMBL26090906 0.74 MEN1 (0.44) ALDH1A1LMNAKMT2ARAB9AMAPT
SCHEMBL6248838 0.73 DRD2 (0.44) SLC18A3AKR1C3AKR1C1ALDH1A1SIGMAR1
SCHEMBL25364244 0.73 RAB9A (0.40) SLC18A3ALDH1A1SIGMAR1GAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009009411-A1 SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-01-15 WO disclosed